Technology
Health
Pharmaceutical

Melinta Therapeutics

$4.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.22 (-5.14%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MLNT and other stocks, options, ETFs, and crypto commission-free!

About

Melinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv, and Minocin for injections. Read More These antibiotics are used in the treatment of infections caused by various bacterial diseases. The company was founded by William L. Jorgensen, Peter Moore, and Thomas A. Steitz in October 2000 is headquartered in New Haven, CT.

Employees
290
Headquarters
New Haven, Connecticut
Founded
2000
Market Cap
18.83M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
167.58K
High Today
$4.27
Low Today
$4.05
Open Price
$4.17
Volume
83.27K
52 Week High
$46.50
52 Week Low
$3.22

Collections

Technology
Health
Pharmaceutical
Therapy
Biopharmaceutical
US
North America

News

Seeking AlphaMar 13

Melinta Therapeutics, Inc. 2018 Q4 - Results - Earnings Call Slides

The following slide deck was published by Melinta Therapeutics, Inc. in conjunction with their 2018 Q4 earnings call. 1 14 Click to enlarge Notes:...

212
Yahoo FinanceMar 13

Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates

Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -91.09% and 99.76%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock? Melinta Therapeutics, Inc. (MLNT) came out with a quarterly loss of $1.93 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $7.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of...

116
Associated PressMar 5

Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019

MORRISTOWN, N.J., March 05, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its fourth quarter and year-end 2018 financial results on March 13, 2019, after the close of the U.S. financial markets. Melinta will host a conference call and live webcast on Wednesday, March 13, 2019 at 4:30 p.m. ET to discuss its financi...

317

Earnings

-$4.33
-$2.94
-$1.56
-$0.17
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$4.33 per share
Actual
-$1.70 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.